Menu
Platform
Solution
Turnkey Multidisciplinary Cancer (MDC) Care Solution
Advanced Tumor Board/MDT Management
Network and Referral Expansion
Patient Tracking, Quality and Accreditation
Patient Loyalty and Survivorship Planning
Cancer Data Access and Insights
Resources
Blog
Case Studies
Education
CME
News
Events
About
Meet Our Leadership Team
Meet Our Board of Directors
Awards
Contact Us
Careers
Platform
Solution
Turnkey Multidisciplinary Cancer (MDC) Care Solution
Advanced Tumor Board/MDT Management
Network and Referral Expansion
Patient Tracking, Quality and Accreditation
Patient Loyalty and Survivorship Planning
Cancer Data Access and Insights
Resources
Blog
Case Studies
Education
CME
News
Events
About
Meet Our Leadership Team
Meet Our Board of Directors
Awards
Contact Us
Careers
SCHEDULE A DEMO
Home
Resources
Education
Stage IA3 Patient with EGFR Exon 19 Deletion Alteration and High-risk DetermaRx Result
Stage IA3 Patient with EGFR Exon 19 Deletion Alteration and High-risk DetermaRx Result
Date Recorded:
March 1, 2021
Recording Length:
20 min
Topics:
EGFR
,
Exon 19 Deletion
,
Lung Cancer
Latest
Sep 22, 2022 | News
Women-Led Digital Health: The Women Behind Digital Health Innovations and the Journey to Success
Read more
Jul 19, 2022 | News
MIB Agents Selects OncoLens to Support and Expand its TURBO Program Globally
Read more
Feb 4, 2022 | News
The Desmoid Tumor Research Foundation Closes Care Gaps through Virtualized Multidisciplinary Cancer Care Platform
Read more
Jan 20, 2022 | News
OncoLens Platform Critical to Meeting the CoC’s Continuous Quality Improvement Requirements
Read more
